{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-037737","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2026-08-13T20:02:19+00:00","discovered_at":"2026-08-13T20:03:01.103681+00:00","generated_at":"2026-08-13T20:03:18.925638+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Daré launches first product Flora Sync LF5, Q2 revenue $0.2M, positive Ovaprene data","bullets":["Launched Flora Sync LF5, first directly commercialized product; revenue began in July 2026.","Q2 2026 total revenue $0.2M vs $(0.02)M YoY; cost of revenues $0.3M.","Cash and equivalents ~$12.6M; working capital deficit ~$0.2M.","Positive interim Phase 3 Ovaprene results; DSMB recommends continue without modification.","DARE to PLAY Sildenafil Cream on track for Q3 2026 dispensing and revenue; prescriptions accepted."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-037737","json":"https://secwatch.observer/filing/0001493152-26-037737.json","markdown":"https://secwatch.observer/filing/0001493152-26-037737.md","text":"https://secwatch.observer/filing/0001493152-26-037737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000149315226037737/0001493152-26-037737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000149315226037737/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:03:18.925638+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}